It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

Moderna

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Moderna signs deal with Shanghai to make mRNA vaccines for Chinese market

Business Jul 6, 2023

Moderna signs deal with Shanghai to make mRNA vaccines for Chinese market

The Massachusetts-based company will work with local government to conduct clinical trials and apply to bring products to market as well as to produce them in China.

Cancer vaccines poised to unlock 'new treatment paradigm' with Merck-Moderna data

World / Science & Health Jun 6, 2023

Cancer vaccines poised to unlock 'new treatment paradigm' with Merck-Moderna data

by Julie Steenhuysen

Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes.

Cancer vaccine hunt makes progress, finally

Commentary / World Apr 21, 2023

Cancer vaccine hunt makes progress, finally

by Lisa Jarvis

A small cancer drug study shows promise in deploying mRNA technology against melanoma, but fighting tumors is vastly more complex than tackling COVID-19.

Moderna-Merck cancer vaccine plus Keytruda delays recurrence of skin cancer

World / Science & Health Apr 17, 2023

Moderna-Merck cancer vaccine plus Keytruda delays recurrence of skin cancer

The findings of the recent trial suggest that adding a personalized cancer vaccine to antibody-based immunotherapy could prolong the time patients have without death or the cancer's return.

Cancer vaccine hunt finally makes progress

Commentary / World Jan 4, 2023

Cancer vaccine hunt finally makes progress

by Lisa Jarvis

A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.

Japan health ministry backs Pfizer and Moderna omicron boosters

National Sep 12, 2022

Japan health ministry backs Pfizer and Moderna omicron boosters

Pfizer’s omicron booster can be administered to people age 12 and over, while Moderna’s is limited to those 18 and above, the panel advised.

What we know about the new omicron vaccines

National / Science & Health | EXPLAINER Aug 12, 2022

What we know about the new omicron vaccines

by Kanako Takahara

New vaccines developed for the COVID-19 omicron variant are scheduled to be available from mid-October in Japan, raising hopes that the population will soon be better protected.

Shionogi confirms efficacy of oral COVID drug for omicron subvariant

National Aug 10, 2022

Shionogi confirms efficacy of oral COVID drug for omicron subvariant

The announcement came after a health ministry panel in July postponed the granting of emergency approval for the drug.

Skin rash more common in women after Moderna shot, Japan study finds

National Jun 3, 2022

Skin rash more common in women after Moderna shot, Japan study finds

by Tomoko Otake

Swelling, pain and/or itchiness of the arm that received the vaccine was also more common among people in their 30s through 60s.

We need better COVID-19 booster shots, not more of the same

Commentary / World Apr 11, 2022

We need better COVID-19 booster shots, not more of the same

by Faye Flam

There are 100 new Covid vaccines in development. One of them could offer better protection against omicron.

With sumo flag sponsorship deal, COVID vaccine-maker Moderna reveals Japan ambition

Business / Corporate Mar 23, 2022

With sumo flag sponsorship deal, COVID vaccine-maker Moderna reveals Japan ambition

by Rocky Swift

The U.S. firm is seeking to build on its newfound renown in COVID-19 vaccines and wrestle market share from compatriot Pfizer Inc.

Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?

National Feb 7, 2022

Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?

by Osamu Tsukimori

Despite an apparent preference among some in the general public for Pfizer, experts have emphasized that getting a booster jab as soon as one is eligible, no matter which type, is key.

VIEW OLDER ARTICLES

  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times